LANXESS Heads Into Q3 Results With Short Score Rising

LANXESS enters its November 5 earnings release with bears gaining ground and the stock at multi-year lows, a setup that makes the next print one of the more closely watched in the European chemicals calendar.

The most notable development this week is not in the lending market, it is in the short score. The ORTEX short score has climbed from 49.3 on October 15 to 55.8 by October 28, a move of more than six points in two weeks. That is a meaningful shift in bearish signal intensity, even if the absolute level is not extreme. The stock itself has shed 3.1% on the week and 4.8% over the past month, closing at EUR 11.73. That puts it well below the cluster of management board purchases in June, when several board members bought in the EUR 15.60 to EUR 16.17 range. The gap between those insider entry levels and the current price is stark.

The lending market tells a calmer story than the rising short score might suggest. Availability is extremely loose: there are roughly 14.3 million shares available to borrow, representing about 1,827% of current short interest. That means the borrow pool is barely touched. The cost to borrow is running at 1.28%, up about 8% on the week but down 17% over the past month, and well below any level that signals stress. Short interest itself is not the story here. At low absolute levels and with utilisation at just 5.8%, the positioning looks more like a modest hedge than a crowd pushing into a conviction short. The short score is rising, but it is rising from a base where actual short positioning is light.

What bulls and bears are debating is essentially a valuation question against a weak macro backdrop. The analyst consensus mean price target is EUR 15.29, roughly 30% above the current price, and the analyst recommendation divergence ranks in the 94th percentile across the ORTEX universe. That unusually wide divergence between where analysts think the stock should be and where the market has it priced reflects deep disagreement about the recovery timeline. EV/EBITDA is running at 5.8x and price-to-book at just 0.31x. The 90-day EPS momentum factor ranks at the 91st percentile, meaning estimate revisions have been unusually positive over that window, while the 30-day EPS momentum has collapsed to the 6th percentile. The Street is split on whether the medium-term estimate recovery is real or a false dawn. Factor scores for short rank (7th percentile) and earnings yield (18th percentile) underline that value screens flag the stock but momentum screens push it away.

Institutional positioning adds a layer of interest. Causeway Capital Management holds the largest disclosed stake at just under 10% of shares, and trimmed slightly as of June 30. American Century added over 600,000 shares through to September 30, and Goldman Sachs Asset Management added nearly 167,000 shares as of October 1. Those are genuinely recent additions. Greenlight Capital, David Einhorn's firm, holds just under 5% as last disclosed in February, a stake that has not moved on record. The management board buying in June, three board members purchasing across EUR 78,000 to EUR 252,000 each, happened at prices roughly 35% above where the stock trades now. That is context, not comfort, for buyers today.

The most recent earnings print, from August 7, was painful: the stock fell 3.6% on the day and 12.7% over the five days that followed. With Q3 results due November 5, that reaction history matters. Peer BASF gained 0.5% on the week while Wacker Chemie fell 4.0%, broadly consistent with continued sector pressure in European specialty chemicals. The divergence between a 30% discount to analyst targets and a short score on a six-week uptrend is the tension worth watching into next Thursday.